the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 0, 1 or 2; R.sup.2 represents hydroxy; --X-- represents C.sub.2-4alkynyl, C.sub.1-12alkyl optionally substituted with hydroxy or X represents a divalent radical of the formula wherein; --X.sub.1-- represents C.sub.1-12alkyl, phenyl or a divalent radical selected from the group consisting of --X.sub.2-- represents C.sub.1-12alkyl, C.sub.1-4alkyloxyC.sub.1-4alkyl, phenyl or a divalent radical of formula --X.sub.3-- represents phenyl or a divalent radical selected from the group consisting of R.sup.1 independently represents hydrogen, C.sub.1-4alkyl, C.sub.1-4alkyloxy-, Ar.sup.1, Ar.sup.2-carbonyl, Het.sup.1-C.sub.1-4alkyl, Het.sup.2, NR.sup.3R.sup.4--C.sub.1-4alkyl, Ar.sup.3-C.sub.1-4alkyloxy- or Het.sup.4-oxy-; R.sup.3 and R.sup.4 each independently represents hydrogen, C.sub.1-4alkyl, C.sub.1-4alkyloxy-, or Het.sup.3; Het.sup.1 represents a heterocycle selected from pyridinyl, indolinyl, indolyl, benzimidazolyl, benzthiazolyl, benzisoxazolyl, thiazolyl, pyridinyl, or thiadiazolyl wherein said Het.sup.1 is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, C.sub.1-4alkyloxycarbonyl-, C.sub.1-4alkyl-, C.sub.1-4alkyloxy- and C.sub.1-4alkyloxy-substituted with halo; in particular Het.sup.1 represents a heterocycle selected from indolyl or pyridinyl; Het.sup.2 represents a heterocycle selected from indolyl, benzisoxazolyl or oxodiazolyl wherein said Het.sup.2 is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, C.sub.1-6alkyl- and C.sub.1-4alkyloxy-; Het.sup.3 represents a heterocycle selected from benzimidazolyl, benzisoxazolyl or benzthiazolyl wherein said Het.sup.3 is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, C.sub.1-6alkyl- and C.sub.1-4alkyloxy-; in particular Het.sup.3 represents benzthiazolyl substituted with C.sub.1-4alkyloxy-; Het.sup.4 represents a heterocycle selected from benzimidazolyl, benzisoxazolyl or benzthiazolyl wherein said Het.sup.4 is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, C.sub.1-6alkyl- and C.sub.1-4alkyloxy-; in particular Het.sup.4 represents benzthiazolyl; Ar.sup.1 represents phenyl optionally substituted with halo, C.sub.1-4alkyl or C.sub.1-4alkyl substituted with one, two or three halo substituents; Ar.sup.2 represents phenyl optionally substituted with halo, C.sub.1-4alkyl or C.sub.1-4alkyl substituted with one, two or three halo substituents; in particular Ar.sup.2 represents phenyl substituted with halo or trifluromethyl; Ar.sup.3 represents phenyl optionally substituted with halo, C.sub.1-4alkyl or C.sub.1-4alkyloxy-.

 
Web www.patentalert.com

< Histone Deacetylase Inhibitors

> Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors

~ 00406